BEACOPPesc

DRUG2 trials

Sponsors

Centre Hospitalier Universitaire Dijon, European Organisation for Research and Treatment of Cancer - EORTC

Conditions

Hodgkin LymphomaHodgkin's Lymphoma

Phase 3

Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL

CompletedNCT01358747

Centre Hospitalier Universitaire DijonHodgkin's Lymphoma

Start: 2011-05-01Updated: 2026-02-09

Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11)

WithdrawnNCT01652261

European Organisation for Research and Treatment of Cancer - EORTCHodgkin Lymphoma

Start: 2013-05-31End: 2014-10-31Updated: 2021-02-15

Related Papers

Distinct Circulating Genomic Features of Classical Hodgkin Lymphoma of Older Adults

Blood2023-11-022 citations

CD20low/CD68high a Promising Microenvironnement Profile Identifying Classical Hodgkin Lymphoma Patients with Poor Outcome a Lysa Study

Blood2023-11-02

Positron Emission Tomography–Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study

Journal of Clinical Oncology2022-01-0639 citations

PET-Guided Strategy Improves the Safety of Beacopp-Based Treatment in Advanced Hodgkin Lymphoma: Prolonged Follow-up of the Lysa Ahl 2011 Phase 3 Study

Blood2020-11-055 citations

PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.

2019-01-15124 citations

Randomized phase III study comparing an early PET driven treatment de-escalation to a not PET-monitored strategy in patients with advanced stages Hodgkin lymphoma: Final analysis of the AHL2011 LYSA study.

Journal of Clinical Oncology2018-05-2013 citations

The Combination of High Expression of CD68-Positive Tumor-Associated Macrophages and PET2-Positivity Predicts Unfavorable Outcome in Patients with Classical Hodgkin Lymphoma Treated in the Lysa AHL2011 Study

Blood2016-12-022 citations

Baseline total metabolic volume (TMTV) to predict the outcome of patients with advanced Hodgkin lymphoma (HL) enrolled in the AHL2011 LYSA trial.

Journal of Clinical Oncology2016-05-2022 citations

Randomized Phase III Study Comparing an Early PET Driven Treatment De-Escalation to a Not PET-Monitored Strategy in Patients with Advanced Stages Hodgkin Lymphoma: Interim Analysis of the AHL2011 Lysa Study

Blood2015-12-0347 citations